IFNG and prostate carcinoma: For instance, a significant reduction in circulating iNKT cells in prostate cancer patients, as well as lower ex vivo expansion of these cells, was found compared to cells from healthy donors [211]; furthermore, prostate cancer patient-derived iNKT cells produced lower levels of IFN-γ, proposing that the anti-tumor capacity of iNKT cells could be compromised by Th2-biased cytokine phenotypes, which was further corroborated by others [210].